Calliditas announces additions to the management team
Calliditas Therapeutics AB (NASDAQ: CALT) announced on July 11, 2022, the addition of two key members to its management team: Sandra Frithiof, Head of Human Resources, and Jonathan Schur, Group General Counsel. Jonathan Schur brings over 40 years of legal experience, particularly in the pharmaceutical sector, while Sandra Frithiof has over 23 years of HR experience across various industries. The company continues its focus on developing treatments for renal and hepatic diseases, with its lead product, TARPEYO, already FDA approved and awaiting European Commission approval.
- Appointment of experienced professionals to the management team.
- TARPEYO, the lead product, has received FDA approval.
- None.
STOCKHOLM, July 11, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the company has added two members to its management team, Head of Human Resources Sandra Frithiof and Group General Counsel Jonathan Schur.
Jonathan Schur has over 40 years of experience as a lawyer, is a member of the New York Bar, and is a former member of the Paris Bar. In private practice he worked with pharmaceutical companies at all stages of development, from biotech companies advancing breakthrough technologies to specialty and large pharmaceutical companies building commercial franchises. Prior to joining Calliditas as Group General Counsel in October 2020, Mr. Schur was a Partner in the Life Sciences practice group at Goodwin Procter LLP, and before that a partner and co-managing partner of the Paris Office of Dechert LLP. He is a graduate of Harvard College and Harvard Law School.
Sandra Frithiof has over 23 years of experience in human resources in different industries. Before joining Calliditas, Sandra worked as Head of HR and COO at Ramberg Advokater, and has also held HR positions at Karolinska University Hospital, UTC, CGI and Manpower Group. She has a bachelor's degree in Human Resource Management from Örebro University, Sweden, and has been the head of HR at Calliditas since 2020. Under her leadership Calliditas has successfully added significant expertise across both Europe and the US.
For further information, please contact:
Marie Galay, IR Manager, Calliditas
Tel.: +44 79 55 12 98 45, email: marie.galay@calliditas.com
The information was sent for publication, through the agency of the contact persons set out above, on July 11, 2022 at 12:30 p.m. CET.
About Calliditas
Calliditas Therapeutics is a commercial stage biopharma company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. Calliditas' lead product, TARPEYOTM (budesonide) delayed release capsules, has been approved by the FDA. This drug product is awaiting European Commission (EC) approval following a positive CHMP opinion. Additionally, Calliditas is conducting a phase 2b/3 clinical trial in primary biliary cholangitis and a Phase 2 proof-of-concept trial in head and neck cancer with its NOX inhibitor product candidate, setanaxib. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on the Nasdaq Global Select Market (ticker: CALT).
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Management Team Addition Eng |
View original content:https://www.prnewswire.com/news-releases/calliditas-announces-additions-to-the-management-team-301583632.html
SOURCE Calliditas Therapeutics
FAQ
What recent management changes occurred at Calliditas Therapeutics (CALT)?
What is the significance of TARPEYO for Calliditas (CALT)?
Where is Calliditas Therapeutics (CALT) based?
What are Calliditas Therapeutics' (CALT) areas of focus?
